Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Horizontal transmission of gut microbiota attenuates mortality in lung fibrosis
Stephen J. Gurczynski, Jay H. Lipinski, Joshua Strauss, Shafiul Alam, Gary B. Huffnagle, Piyush Ranjan, Lucy H. Kennedy, Bethany B. Moore, David N. O’Dwyer
Stephen J. Gurczynski, Jay H. Lipinski, Joshua Strauss, Shafiul Alam, Gary B. Huffnagle, Piyush Ranjan, Lucy H. Kennedy, Bethany B. Moore, David N. O’Dwyer
View: Text | PDF
Research Article Microbiology Pulmonology

Horizontal transmission of gut microbiota attenuates mortality in lung fibrosis

  • Text
  • PDF
Abstract

Pulmonary fibrosis is a chronic and often fatal disease. The pathogenesis is characterized by aberrant repair of lung parenchyma, resulting in loss of physiological homeostasis, respiratory failure, and death. The immune response in pulmonary fibrosis is dysregulated. The gut microbiome is a key regulator of immunity. The role of the gut microbiome in regulating the pulmonary immunity in lung fibrosis is poorly understood. Here, we determine the impact of gut microbiota on pulmonary fibrosis in substrains of C57BL/6 mice derived from different vendors (C57BL/6J and C57BL/6NCrl). We used germ-free models, fecal microbiota transplantation, and cohousing to transmit gut microbiota. Metagenomic studies of feces established keystone species between substrains. Pulmonary fibrosis was microbiota dependent in C57BL/6 mice. Gut microbiota were distinct by β diversity and α diversity. Mortality and lung fibrosis were attenuated in C57BL/6NCrl mice. Elevated CD4+IL-10+ T cells and lower IL-6 occurred in C57BL/6NCrl mice. Horizontal transmission of microbiota by cohousing attenuated mortality in C57BL/6J mice and promoted a transcriptionally altered pulmonary immunity. Temporal changes in lung and gut microbiota demonstrated that gut microbiota contributed largely to immunological phenotype. Key regulatory gut microbiota contributed to lung fibrosis, generating rationale for human studies.

Authors

Stephen J. Gurczynski, Jay H. Lipinski, Joshua Strauss, Shafiul Alam, Gary B. Huffnagle, Piyush Ranjan, Lucy H. Kennedy, Bethany B. Moore, David N. O’Dwyer

×

Figure 3

Substrain C57BL/6 mice demonstrate varied patterns of dysbiosis that associate with mortality and lung fibrosis.

Options: View larger image (or click on image) Download as PowerPoint
Substrain C57BL/6 mice demonstrate varied patterns of dysbiosis that ass...
Here, we analyzed the response of gut microbiota during stages of acute lung injury (day 7 after bleomycin), transition of lung fibrosis (day 14), and advanced lung fibrosis (study end) using 16S rRNA amplicon sequencing in CR and JAX substrain mice. (A) Bray-Curtis dissimilarity scores show a significant increase in dissimilarity from baseline (day 0) to day 7 in JAX mice, demonstrating an increased susceptibility to gut dysbiosis. (B) No significant difference between groups in abundance of Clostridiales over time. (C) Significant decrease in the abundance of potentially antiinflammatory Lactobacillaceae by day 7 after bleomycin with persistently higher levels of Lactobacillaceae in CR mice compared with JAX mice over time. (D) Significant increase in abundance of Deferribacteraceae in CR mice after bleomycin correlating with survival; this taxon was undetectable in JAX mice. (E–G) Significant increases in Erysipelotrichaceae and Ruminococcaceae over time in JAX mice after bleomycin compared with CR mice, with significant increase in Verrucomicrobiaceae in both CR and JAX mice; however, the effect size is significantly greater in JAX mice, and abundance remains higher in JAX mice over time. (H) The relative abundance of gut Lactobacillaceae at baseline is associated with a reduced risk of mortality; mice with a relative abundance greater than 1.42% (median) were protected from mortality (log rank P < 0.001). (I) An increased relative abundance of gut Verrucomicrobiaceae at baseline was associated with an increased risk of mortality, mice with a relative abundance greater than 5.55% of total communities were at significantly greater risk of mortality (log rank P = 0.03). (J) CR mice demonstrated significantly higher α diversity measured by Shannon diversity indices throughout the experiment. (A–J n = 20 per group.) Unpaired t test or Mann-Whitney test where applicable (A), multiple t test per row with multiple comparison corrections where applicable (B–G and J), KM survival estimates and log rank test (H and I). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts